Last reviewed · How we verify
immunotherapy with dendritic cells
At a glance
| Generic name | immunotherapy with dendritic cells |
|---|---|
| Sponsor | Clinica Universidad de Navarra, Universidad de Navarra |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) (PHASE2)
- PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PHASE1)
- Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer (PHASE2)
- IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma (PHASE1)
- Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer (PHASE1, PHASE2)
- DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |